Professor Dr. Luisa Maria Arvide Cambra, Spanish is now Professor with Chair at the University of Almería (Spain) and she was Assistant Professor and Associate Professor at the University of Granada from 1979 on.

Thirty nine years of the teaching and researching experience. She is the Director of Research Group HUM113-Estudios Filológicos from Program of Research of Andalusian Government, where she has managed and directed several academic and scientific contracts and research projects, as well as a Member of Athens Institute for Education & Research (ATINER) in Greece, The Academic Genesis Platform (UAGP) in UK&Turkey and Experts of Academic Excellence Research Centre (EAERC) in Jordan; etc.

She is author of a many works on several aspects of the Arabic science and literature in the Middle Ages, as well as Arabic language and linguistics. She has also participated in different prestigious international scientific Conferences. She has visited a many universities and academic institutions of Europe, United States and Arab countries in order to teach and research. Among her works, we have the study and the translation to Spanish of some treatises of Kitab al-tasrif´s Al-Zahrawi, Ibn Qutayba´s texts, Maqamas of Al-Hariri, The Sicilian Questions of Ibn Sab´in, etcetera.

Prof. Arnon Blum received his MD at the Technion, specialized in Internal Medicine at Hebrew University, and then in Cardiology at Tel-Aviv University. He served in the IDF as a Flight Surgeon (Lieutenant Colonel). Since 1999 Prof. Arnon Blum has been the Director of the Internal Medicine Ward at Baruch Padeh Medical Center—Poriya, Tiberias. Prof. Blum further concentrated on Vascular Biology and Vascular Stem Cell research, receiving his training at the National Institutes of Health (Bethesda, MD, USA; 1997-1999 and 2006-2008) exploring means for cardio-vascular regeneration. In 2011-12, he was invited as a visiting Professor to lead a clinical trial at the University of Miami for adult (mesenchymal) stem cell transplants to patients with severe heart failure. There, he discovered a key mechanism that explains the beneficial effects of cell transplantation to the failing heart.

Prof. Blum has published more than 160 papers in peer-reviewed journals as well as chapters in invasive cardiology textbooks – the most recent one addressing techniques for stem cell transplantation to the heart (Grossman 8^th edition, 2014). He serves on the editorial board of 15 journals in Cardiology, Internal Medicine and Translational Medicine, and is the Editor in Chief of one of these. Prof. Blum is a member of 5 steering committees at Bar-Ilan University’s School of Medicine in the Galilee. His main goal now is to build a Center of Excellence in Regenerative Medicine at the School of Medicine in the Galilee, which will focus on cardiovascular regeneration and include basic research and clinical facilities.

Segundo Mesa Castillo. As Specialist in Neurology, he worked for 10 years in the Institute of Neurology of Havana, Cuba.  He has worked in Electron Microscopic Studies on Schizophrenia for 32 years. He was awarded with the International Price of the Stanley Foundation Award Program and for the Professional Committee to work as a fellowship position in the Laboratory of the Central Nervous System Studies, National Institute of Neurological Diseases and Stroke under Dr. Joseph Gibbs for a period of 6 months, National Institute of Health, Bethesda, Maryland, Washington D.C. USA, June 5, 1990. At present he is member of the Scientific Board of the Psychiatric Hospital of Havana and give lectures to residents in psychiatry.

Dr. Brij. M. Gandhi, M.Sc.(Biochemistry) and Ph.D.(Experimental Medicine, Norway) is presently CEO and founder of Neo BioMed Services (www.neobiomed.com), providing services and consultancy in health areas and regulatory issues related to biopharmaceuticals, pharmaceuticals, including stem cell and regenerative medicine. As Adviser to the Government of India, Dr. Gandhi  was involved in management, promotion and policy issues in biotechnology related to international collaborations, medical biotechnology, infrastructure development, animals and aquaculture biotechnology, biosafety and biosecurity. Prior to that he was Research Scientist at AIIMS, New Delhi working on immunology of parasitic, bacterial and viral infections including amoebic diseases; hepatitis; liver diseases, IVD, food and nutritional health issues.

Dr. Gandhi was trained at MIT, USA; LSHTM, London, NIH, USA, Hvidovre Hospital, Copenhagen and University of Bergan, Norway. Dr. Gandhi continues to serve as Advisor / Director to a number of institutions/pharma and biopharma industries with an experience of about 50 years as research scientist, science  manager, adviser/consultant and having over 155 publications.

Prof . Oron is current a full professor at Tel-Aviv University in Israel. Prof Oron received his Ph.D. in Cell Biology from Tel-Aviv University, Israel in 1977. From 1977 he spent 2 years of post- doctoral fellowship at Harvard University on muscle physiology and since 1979 serves as a faculty member at Tel-Aviv University. He specializes in the effect of photobiomodulation (PBM ) on biological processes post myocardial infarction ,stroke and brain injury in experimental animals and humans. Recently his studies involve PBM of stem cells in the bone marrow for the benefit of the ischemic heart. He has been invited to speak and chair at numerous international PMB conferences and served as a reviewer for various PMB journals. He has published over 90 peer reviewed articles and chapters in books; 40 of them in the field of PBM therapy.

Marek Łos studied medicine at Jagiellonian Univ., Krakow, Poland. He obtained his doctoral degree from Univ. Heidelberg, in 1995, and habilitation (academic teaching license) in Molecular Medicine, from Univ. Muenster in 2002. He is currently the director of Biotechnology Center, Silesian University of Technology, Poland. He is also assoc. editor at The European Journal of Pharmacology, holds 3 Visiting Professorships at 2 Polish universities and the Jinan University (Guangzhou, China), and a ‘Senior Scientific Adviser’ position at Linkocare AB, Linköping, Sweden. Linkocare’s core business is the production of artificial corneas. Dr. Łos (co-)authors about 150 scientific papers, some of them highly-cited, edited several books and volumes. He has been serving as member of a number of editorial boards of scientific journals, as well as on various grant review committees in the Europe and in Canada. Dr. Łos pursues various research projects within area of oncology, targeted cancer therapies and Regenerative Medicine. His most important scientific achievements were the description of involvement of caspase family of proteases in CD95 (APO-1/Fas) mediated apoptosis, (Los et al., 1995; Nature 375: 81-83), and the discovery of the role of kinase Akt both in the regulation of cell survival and cell death of cancer cells (Maddika et al., 2008, J. Cell Sci.; Maddika et al., 2009, Mol. Cell. Biol.). His research interest encompasses cancer immunology, cell death execution pathways, as well as cancer stem cell biology, epigenetic reprogramming (production of iPS-cells), as well as transdifferentiation technologies.

LIPOGEMS adipose tissue graft ad an ideal regenerative bioreactor. State of the art and clinical experience over a 6 years period

Generation of (corneal) limbal cells from somatic cells - comparison of reprogramming and transdifferentiation